USANA (USNA) Q4 2025 earnings review
Transformation Pain: Sales Grow, Earnings Evaporate
USANA's strategic pivot from a pure-play direct seller to an omnichannel health company is generating top-line growth but crushing profitability. While Q4 revenue rose 6% YoY to $226.2M, driven by acquisitions (Hiya, Rise), the company swung to a $1.8M Net Loss due to impairments and restructuring costs. The legacy direct-selling business continues to atrophy, with active customers down 15% YoY. FY26 guidance projects a further decline in the core business, banking entirely on explosive 300%+ growth in the new 'Rise Wellness' segment to sustain the top line.
🐂 Bull Case
The Rise Wellness segment is guiding for massive acceleration, from ~$16M in sales in FY25 to $65-80M in FY26. Expansion of 'Protein Pop' into club retail channels is a tangible catalyst for diversification.
Sequential active customer counts in the core business were effectively flat (388k in Q3 to 387k in Q4) after steep declines, suggesting the worst of the direct-selling exodus may be pausing.
🐻 Bear Case
Despite management claims of 'solid growth,' Hiya active subscribers dropped sequentially from 193,400 in Q3 to 181,700 in Q4. This contradicts the growth narrative for the company's primary acquisition engine.
The shift to retail and DTC is hurting margins. Q4 Adjusted EBITDA margin compressed to 12.1% (vs ~15% historical norms), and the Core Nutritional business—the primary profit generator—is guided to decline another 0-5% in FY26.
⚖️ Verdict: 🔴
Bearish. The 'transformation' is proving costly and uneven. While Rise Wellness is a bright spot, the sequential subscriber loss in Hiya and the relentless decline of the high-margin core business create significant earnings uncertainty.
Key Themes
Hiya Subscriber Contraction
A critical red flag appeared in the data: Hiya Active Monthly Subscribers fell 6% sequentially (193,400 in Q3 to 181,700 in Q4). This directly contradicts the narrative of 'continued strength in core direct-to-consumer business.' Customer acquisition challenges cited in Q3 appear to be persisting.
Rise Wellness Explosion
The bright spot in guidance is Rise Wellness (Rise Bar/Protein Pop). Management forecasts FY26 sales of $65-80M, roughly a 4x increase from implied FY25 levels (~$16M). This segment is graduating from an experiment to a major revenue pillar, driven by club retail distribution.
Core Business Erosion Continues
The legacy direct-selling business remains in secular decline. Q4 Net Sales in Asia Pacific fell 10% YoY, and Active Customers globally dropped 15% YoY (454k to 387k). FY26 guidance confirms this trend is not reversing, projecting a further 0-5% revenue decline for the segment.
Profitability Under Pressure
The shift in business mix is diluting earnings quality. Adjusted Diluted EPS for FY26 is guided at $1.95-$2.29, which at the midpoint ($2.12) is barely above FY25's depressed $1.93 and well below FY24's $2.59. Moving into retail (Rise) and DTC (Hiya) typically carries lower margins than direct selling.
One-Time Charges Masking Performance
GAAP results were heavily impacted by a $7.0M goodwill impairment (due to stock price decline) and $6.5M in cost realignment charges. While 'one-time' in nature, these charges pushed the company into a net loss for the quarter and signal recognized destruction of shareholder value.
Other KPIs
Stable. Increased 7% YoY, but margin remains compressed at 12.1% compared to historical highs. The company is struggling to translate top-line growth from acquisitions into meaningful profit expansion.
Negative Trend. Inventory spiked 48% YoY ($35M increase). Management cites support for Rise Wellness growth and raw material ramping for in-house Hiya production, but this represents a significant drag on working capital.
Decelerating. Down 10% YoY. Greater China, the company's most critical market, fell 11% YoY. The core growth engine of the past decade is sputtering.
Guidance
Stable/Accelerating. Midpoint implies ~4% growth. However, quality of growth is mixed: mostly driven by lower-margin Rise and Hiya segments while the core cash cow shrinks.
Decelerating/Negative. Guidance implies a 2% to 7% decline vs FY25 levels (derived ~ $777M). Management's 'stabilization' narrative is not supported by their own revenue forecast.
Accelerating. Implies massive growth from <$20M in FY25. This is the primary 'good news' story in the report, dependent on successful retail execution.
Stable. Midpoint ($2.12) represents ~10% growth over FY25's $1.93, but remains significantly below FY24 levels ($2.59). Earnings recovery is lagging revenue recovery.
Key Questions
Hiya Subscriber Drop
You reported Hiya active subscribers dropped from 193,400 in Q3 to 181,700 in Q4. Given the emphasis on Hiya as a growth engine, what caused this churn, and why should investors trust the +6-17% growth guidance for FY26?
Rise Wellness Margins
With Rise Wellness revenue projected to quadruple via club retail channels, what is the expected impact on consolidated gross margin? Are we trading profitable direct sales dollars for lower-margin retail dollars?
Core Business Floor
Guidance implies continued declines in the Core Nutritional business. With active customers down 15% YoY, do you see a floor for this segment in FY26, or is this a managed decline?